rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Waters Corporation

WAT · NYSE

Health CareLife-science toolsLeading

WAT stood above a rising 150-day average in 28 of the last 52 weekly readings, including each of the last 11 weeks. It is 22.5% above that average now. Life Science Tools & Research Services: 58% of its 79 stocks in an uptrend (+6 points in four weeks); Health Care: 28% (−6 points in four weeks).

Statistics

Rotation
Leading
Weeks in an uptrend
11 in a row
Industry in uptrend
58% +6 in 4 wk
Insider buys, 12 months
$902K
Insider sales, 12 months
$2.9M
Officials’ trades on record
40

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 28 of 52 weeks.

22 Apr – 21 Oct
26%42%57%Apr 26Jun 26Jul 26Sep 26Oct 26

Life-science tools: About half its stocks are in an uptrend and the share has been climbing. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$2.7M$0$766KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars. Not yet read: institutions.

Congress and officials

40 disclosed lines: House 28, Senate 4, executive 8; 14 people.

WhoDidAmountTraded
Kevin Hern House: U.S. House ClerkOK01soldjoint$1k–$15k13 Aug 2026filed 1 Sep 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$15k–$50k12 Jun 2026filed 22 Aug 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$1k–$15k15 Apr 2026filed 1 Jul 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$1k–$15k23 Mar 2026filed 14 May 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$15k–$50k18 Mar 2026filed 14 May 2026
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31bought$1k–$15k18 Mar 2026filed 7 Apr 2026
Thomas H. Kean, Jr. House: U.S. House ClerkNJ07sold$1k–$15k10 Mar 2026filed 13 Apr 2026
Thomas H. Kean, Jr. House: U.S. House ClerkNJ07sold$1k–$15k13 Feb 2026filed 18 Mar 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$100k–$250k11 Feb 2026filed 14 May 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$100k–$250k10 Feb 2026filed 14 May 2026
Debbie Dingell House: U.S. House ClerkMI06exchanged$1k–$15k10 Feb 2026filed 23 Feb 2026
Kevin Hern House: U.S. House ClerkOK01exchangedjoint$1k–$15k9 Feb 2026filed 6 Mar 2026

Insiders

Buy orders, 12 months2
Sale orders, 12 months1
Buyers · sellers2 · 1
WhoDidSharesTraded
Christopher A. KueblerDirectorsold3,626at $397.946 Aug 2026filed 7 Aug 2026
Wei JiangDirectorbought500at $289.4616 Mar 2026filed 18 Mar 2026
Richard H. FearonDirectorbought1,000at $306.346 Mar 2026filed 10 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Still reading this part; it fills in a moment.

Everyone who traded it

Heather Knight Company insiderDirector · last 30 Sep 20260 · 0
Wei Jiang Company insiderDirector · last 30 Sep 20261 · 0
Kevin Hern HouseOK01 · last 13 Aug 20260 · 1
Christopher A. Kuebler Company insiderDirector · last 6 Aug 20260 · 11
Robert L. Carpio III Company insiderSVP Waters Analytical Sciences · last 24 Jun 20260 · 0
Donald J. Trump Executive branchWhite House Office · last 12 Jun 20265 · 3
Amol Chaubal Company insiderSVP & Chief Financial Officer · last 12 May 20260 · 0
Jianqing Bennett Company insiderSVP Waters Adv. Diagnostics · last 6 Apr 20260 · 0
Gilbert Ray Cisneros, Jr. HouseCA31 · last 18 Mar 20265 · 0
Thomas H. Kean, Jr. HouseNJ07 · last 10 Mar 20260 · 2
Richard H. Fearon Company insiderDirector · last 6 Mar 20262 · 0
Udit Batra Company insiderPresident and CEO · last 2 Mar 20260 · 0

Same industry

OABI OmniAbLeading+72%
TXG 10x GenomicsLeading+69%
ILMN IlluminaLeading+53%
AVTR AvantorLeading+52%
RVTY RevvityLeading+39%
ABSI AbsciLeading+36%
MASS 908 DevicesLeading+35%

Distance from each stock’s own 150-day average.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202561.1%
Operating profit marginFY 2025 · to 31 Dec 202586.1%
Free cash flow marginFY 2025 · to 31 Dec 202557.9%
Return on capital employedFY 2025 · to 31 Dec 202520.9%
Cash conversionFY 2025 · to 31 Dec 2025102%
Debt to equityFY 2025 · to 31 Dec 20250.55×
Interest coverFY 2025 · to 31 Dec 202556.18×
Research spendFY 2025 · to 31 Dec 20255.0%
Revenue growthFY 2025 · to 31 Dec 202516.6%
Earnings per share growthFY 2025 · to 31 Dec 2025330%
Share count trendFY 2025 · to 19 Feb 202664.7%
Cash and equivalentsFY 2025 · to 31 Dec 2025$587.8M

Analyst forecasts

No analyst forecasts yet.